Array Technologies looks deeply undervalued after a 91% drop, with strong FCF yield and solar tailwinds. See why ARRY stock ...

Fory 1.7.0 release also expands Swift platform support and supports incremental JSON stream decoding for top-level arrays and ...

Indian-origin Nasa astronaut Anil Menon is set to conduct his first spacewalk outside the International Space Station (ISS) on Thursday, joining veteran astronaut Jessica Meir for a seven-hour ...

OPPD opened its newest generation facilities with a ribbon cutting ceremony as well as a ground breaking for a third one to be built The Omaha Public Power District announced Wednesday that it has ...

Matthew Rodriguez is a digital producer for CBS Los Angeles. He's previously reported for local outlets like the Argonaut and Pasadena Weekly. Matt typically covers breaking news and crime. Julie ...

As more and more data centers are proposed throughout the region and the state, the issues critics bring to the table are becoming fairly familiar — the amount of water used to cool the servers, air ...

Has Elon Musk given up on Tesla’s Master Plans, on the electrified economy, on solar power as we know it? From the SpaceX IPO filing released this week, it sure seems like it. A recap for those not ...

Pragmata's map is bigger and more full of secrets than you might expect from what initially seems like a series of hallways. Nooks filled with danger and crannies hiding treasure abound, but it's easy ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...